Iovance Biotherapeutics (IOVA) Cash & Equivalents (2010 - 2026)

Iovance Biotherapeutics (IOVA) has reported Cash & Equivalents for 16 consecutive years, with $196.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents rose 14.47% year-over-year to $196.5 million; the TTM figure through Mar 2026 stood at $196.5 million (up 14.47% YoY), while the FY2025 annual figure was $163.1 million, up 40.96% from the prior year.
• Cash & Equivalents grew to $196.5 million in Q1 2026 per IOVA's latest filing, from $163.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $543.5 million in Q1 2023 and bottomed at $92.4 million in Q1 2022.
• Historically, Cash & Equivalents has averaged $186.5 million across 5 years, with a median of $163.1 million in 2025.
• Annual changes were most pronounced in 2023 — Cash & Equivalents surged 488.44% — and 2024, when it slumped 75.31%.
• Iovance Biotherapeutics' Cash & Equivalents stood at $231.7 million in 2022, then slumped by 50.42% to $114.9 million in 2023, then rose by 0.7% to $115.7 million in 2024, then soared by 40.96% to $163.1 million in 2025, then advanced by 20.5% to $196.5 million in 2026.
• Business Quant data shows IOVA's Cash & Equivalents at $196.5 million in Q1 2026, $163.1 million in Q4 2025, and $158.1 million in Q3 2025.